By Bill Holt, DO, Vice President, Neuroscience Therapeutic Area, ICON
For neurologic monoclonal antibodies (mAbs), the scientific hurdle is no longer the primary barrier to success. Increasingly, operational execution—not efficacy—determines whether these therapies reach patients at scale. From multiple sclerosis (MS) to neuromyelitis optica spectrum disorder (NMOSD) to early Alzheimer’s disease, mAbs have moved from experimental ambition to a daily clinical priority with well-understood mechanisms of action, a substantial body of published clinical evidence and general acceptance within the standard of care.
What’s less well understood is why some neurologic mAb therapies reach patients reliably and others don’t. The answer, increasingly, isn’t found in data on clinical efficacy. It’s in the operational infrastructure surrounding these drugs. This is most easily glimpsed in the protocols that govern how these therapies are delivered, monitored and managed once they reach clinical practice.
A Small Protocol Item With a Crucial Lesson
For example, consider what happens when a patient with NMOSD begins treatment with a complement inhibitor such as eculizumab or ravulizumab. Prior to the first dose, the patient must be vaccinated against meningococcal disease. This isn’t a precaution drawn from post-market observation. It follows directly from the drug’s mechanism of action.
By blocking complement protein C5, these therapies impair the formation of the membrane attack complex, the immune system’s front-line defense against encapsulated bacteria such as Neisseria meningitidis. The meningococcal infection risk is a direct and foreseeable consequence of the drug’s mechanism of action, and the vaccination requirement follows from that biological reality, not from a regulatory checkbox exercise.
That distinction deserves more credit than it typically receives. It represents exactly the kind of indication-specific safety thinking the broader neurologic mAb field increasingly demands, and that development programs must treat as a critical day-one component, not an afterthought.
Safety Patterns, Not Exceptions
The meningococcal vaccination protocol for C5 inhibitors isn’t an isolated case. A survey of the neurologic mAb landscape reveals the same principle surfacing repeatedly. Safety governance is bespoke to the various mechanisms of action rather than applied generically across drug classes.
Natalizumab, used in the treatment of MS, carries a risk evaluation and mitigation strategy (REMS) program — the TOUCH® Prescribing Program — that requires ongoing monitoring of anti-JC virus antibody status. Elevated antibody levels are a strong predictor of progressive multifocal leukoencephalopathy (PML), a potentially fatal opportunistic brain infection and a predictable consequence of how natalizumab modulates lymphocyte trafficking.
This pattern holds more broadly. Anti-CD20 therapies for MS require hepatitis B virus screening before treatment initiation, because B-cell depletion creates specific conditions conducive to viral reactivation. Anti-amyloid therapies for early Alzheimer’s disease require strict MRI monitoring cadence, because amyloid-related imaging abnormalities, including brain edema and microhemorrhage detectable only on imaging, are a known consequence of the amyloid clearance mechanism itself.
Each of these safety frameworks is different, reflecting the specific biology of the therapy it governs. And each requires its own workflows, documentation standards and staff training that cannot be templated from another indication. Developers who approach safety planning as a generic compliance function, rather than a mechanism-specific development requirement, will eventually pay a steep price for that assumption.
The Operational Gap
Natalizumab’s story is instructive in another way. When first approved, its dramatic efficacy in relapsing MS was matched only by the severity of the PML risk it carried. The U.S. Food and Drug Administration’s response was the REMS requirement, a mandatory restricted distribution program that permanently embedded safety governance into the prescribing workflow and marked a turning point for the entire field. It established that operational infrastructure wasn’t a support function, but a condition of access.
That lesson has expanded in the years since. Today, the clinical reality for neurologic mAbs is that approval and access are no longer the same thing. A therapy can clear regulatory review and still fail to reach the patients who need it when eligibility protocols aren’t embedded in the clinical workflow, when imaging cadence strains site capacity, or when registry documentation isn’t in place before the first dose is administered.
The Centers for Medicare & Medicaid Services’ coverage-with-evidence requirement for anti-amyloid Alzheimer’s therapies makes this explicit. Medicare reimbursement is contingent on patient enrollment in a registry designed to collect real-world evidence. This is an operational requirement that must be satisfied before the first clinical dose is administered, not retrofitted afterward. For health systems unprepared for that documentation burden, the practical effect is a barrier to patient access that has nothing to do with clinical eligibility.
This is the operational gap, the growing distance between scientific investment and operational investment in drug development budgets. It is a gap that is becoming increasingly costly but isn’t necessarily prohibitive. In practice, this gap manifests as delayed site activation, under-enrolled registries, missed monitoring windows, and ultimately restricted access despite regulatory approval.
Start Earlier
The answer isn’t more operational resources at launch. It’s earlier operational thinking during development. Indication-specific safety frameworks, device and administration decisions, site capacity modeling, and registry architecture are not pre-launch logistics. They are development decisions with long-tailed downstream consequences, and they need to be treated as such from at least Phase 2 onward.
The clinical evidence for neurologic mAbs is compelling, but the therapies that will define the next decade of neurologic care won’t be distinguished only by their biology. They will be distinguished by the operational discipline that surrounds them, the frameworks that ensure a drug that works in a trial also works in a clinic, reliably, at scale, and for the patients who need it most. The operational infrastructure that converts scientific success into patient access is just as critical as the science.
As neurologic mAbs expand into earlier disease stages and larger patient populations, operational complexity will increase rather than decrease—particularly with combination therapies and decentralized monitoring approaches. Programs that anticipate this complexity during development will have a disproportionate advantage at launch.
In neurologic mAb development, scientific success is no longer sufficient. The therapies that reach patients will be those designed not only to work, but to be delivered.
Dr. Holt, VP, ICON Drug Development Services, is a neurologist, board certified in psychiatry and neurology with sub-specialty certification in both vascular neurology and neurorehabilitation. Prior to joining ICON, he was CEO at Neurostudies, Inc, a research center focused on neuroscience clinical trials. In his current role, Dr. Holt is responsible for the strategic review of protocols to provide recommendations regarding choice of subject population, endpoints, inclusion/exclusion criteria and consultation with sponsors in development of clinical trial programs.
Sponsored content by ICON
